Bio

Clinical Focus


  • Obstetrics and Gynecology

Administrative Appointments


  • Associate Director, Reproductive Endocrinology & Infertility Fellowship (2015 - Present)

Professional Education


  • Board Certification: Reprod. Endocrinology and Infertility, American Board of Obstetrics and Gynecology (1994)
  • Board Certification: Obstetrics and Gynecology, American Board of Obstetrics and Gynecology (1990)
  • Internship:Loma Linda University School of Medicine RegistrarCA
  • Fellowship:University of Vermont-Fletcher Allen Health CareVT
  • Medical Education:Saint Louis University (1982) MDUnited States of America
  • Residency:Loma Linda University - School of MedicineCA

Publications

All Publications


  • PRE-IMPLANTATION GENETIC TESTING (PGT-A) USING FAST-SEQS NGS OF IN VIVO CONCEIVED BLASTOCYSTS RECOVERED BY UTERINE LAVAGE. Alouf, C. A., Najmabadi, S., Nakajima, S. T., Buster, J. E., Faulkner, N. ELSEVIER SCIENCE INC. 2019: E238?E239
  • EXOGENOUS GONDOTROPIN USE NOT ASSOCIATED WITH INCREASE IN ANEUPLOIDY OF IN VIVO RECOVERED BLASTOCYSTS. Nakajima, S. T., Najmabadi, S., Munne, S., Nadal, A., Choudhary, K., Buster, J. E. ELSEVIER SCIENCE INC. 2019: E135
  • Relationship between paternal somatic health and assisted reproductive technology outcomes. Fertility and sterility Eisenberg, M. L., Li, S., Wise, L. A., Lynch, C. D., Nakajima, S., Meyers, S. A., Behr, B., Baker, V. L. 2016; 106 (3): 559-565

    Abstract

    To study the association between paternal medical comorbidities and the outcomes of assisted reproductive technology (ART).Retrospective cohort study.Academic reproductive medicine center.We analyzed fresh ART cycles uszing freshly ejaculated sperm from the male partner of couples undergoing ART cycles from 2004 until 2014. We recorded patient and partner demographic characteristics. The cohort was linked to hospital billing data to obtain information on selected male partners' comorbidities identified using ICD-9-CM codes.None.Fertilization, clinical pregnancy, miscarriage, implantation, and live-birth rates as well as birth weights and gestational ages.In all, we identified 2,690 men who underwent 5,037 fresh ART cycles. Twenty-seven percent of men had at least one medical diagnosis. Men with nervous system diseases had on average lower pregnancy rates (23% vs. 30%) and live-birth rates (15% vs. 23%) than men without nervous system diseases. Lower fertilization rates were also observed among men with respiratory diseases (61% vs. 64%) and musculoskeletal diseases (61% vs. 64%) relative to those without these diseases. In addition, men with diseases of the endocrine system had smaller children (2,970 vs. 3,210 g) than men without such diseases. Finally, men with mental disorders had children born at an earlier gestational age (36.5 vs. 38.0 weeks).The current report identified a possible relationship between a man's health history and IVF outcomes. As these are potentially modifiable factors, further research should determine whether treatment for men's health conditions may improve or impair IVF outcomes.

    View details for DOI 10.1016/j.fertnstert.2016.04.037

    View details for PubMedID 27179785

  • Practice patterns, satisfaction, and demographics of reproductive endocrinologists: results of the 2014 Society for Reproductive Endocrinology and Infertility Workforce Survey FERTILITY AND STERILITY Barnhart, K. T., Nakajima, S. T., Puscheck, E., Price, T. M., Baker, V. L., Segars, J. 2016; 105 (5): 1281-1286

    Abstract

    To identify the current and future state of the practice of reproductive medicine.Cross-sectional survey.Not applicable.None.Not applicable.The survey included 57 questions designed to assess practice patterns/metrics and professional satisfaction and morale.A total of 336/1,100 (31%) responded, and they were 38% women, 61% men, and 76% Caucasian, with a mean age of 54. Respondents averaged 2.3 jobs and averaged 53 hours of work per week: 44% work in academia and 50% in private groups. Average practice size was 5.5, with an average of 470 fresh IVF cycles performed per year. Percent effort included 63% infertility, 10% endocrinology, 10% surgery, and 9% research. Respondents performed an average of 13 major surgeries, 69 minor surgeries, and 128 oocyte retrievals per year. A total of 60% were salaried, and 40% were equity partners. Compensation was highly skewed. Greater than 84% had a positive morale and had a positive view of the future, and 92% would again choose REI as a career. The most satisfying areas of employment were patient interactions, intellectual stimulation, interactions with colleagues, and work schedule. The least satisfying areas were work schedule and financial compensation. Training was felt to be too focused on female factor infertility and basic research with insufficient training on embryology, genetics, male factor infertility, and clinical research. In the next 5 years, 57% suggested that the need for specialists would stay the same, while 20% predicted a decrease. A total of 58% felt we are training the correct number of fellows (37% felt we are training a surplus). Compared with academia, those in private practice reported higher compensation, less major surgery, more IVF, less endocrinology, and less research. Men worked more hours, conducted more surgery and IVF cycles, and had higher compensation than women. Morale was similar across age, gender, practice type, and geography.Our subspecialty has an extremely high morale. We are a middle-aged subspecialty with disparate compensation and a focused practice. Some respondents sense a need for a change in our training, and most anticipate only mild growth in our field.

    View details for DOI 10.1016/j.fertnstert.2015.12.135

    View details for Web of Science ID 000375871200036

    View details for PubMedID 26774576

  • Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive CONTRACEPTION Nakajima, S. T., Pappadakis, J., Archer, D. F. 2016; 93 (1): 52-57

    Abstract

    Safe and effective contraceptive options for obese women are becoming more important due to the obesity epidemic within the United States. This study evaluated the impact of body mass index (BMI) on efficacy, safety and bleeding patterns during use of an ultra-low-dose combined oral contraceptive (COC).Data are from a Phase 3 clinical efficacy and safety study of an ultra-low-dose COC containing 1.0-mg norethindrone acetate and 10-mcg ethinyl estradiol. Pearl Indices, adverse events and bleeding profile were calculated for BMI ranges of <25, 25-30 and >30 kg/m(2).Of the 1581 participants included in the analysis, 28.3% were overweight, and 18.0% were obese. For women aged 18-45 years, the Pearl Indices were 2.49, 2.32 and 1.89 for women with a BMI <25, 25-30 and >30 kg/m(2), respectively. The ultra-low dose of ethinyl estradiol did not impact scheduled bleeding or intensity of bleeding, but we observed a slight decline in amenorrhea and slight increase in unscheduled bleeding in obese women compared with other BMI categories.Our analysis of an ultra-low-dose COC did not find clinically important differences in contraceptive failure rates, adverse events or bleeding profile with increasing BMI.Our analysis of an ultra-low ethinyl estradiol dose COC did not find clinically important differences in contraceptive failure rates, adverse events or bleeding profile with increasing BMI. An ultra-low-dose COC provides another safe and effective contraceptive option for obese women.

    View details for DOI 10.1016/j.contraception.2015.09.013

    View details for Web of Science ID 000367409600008

  • Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive. Contraception Nakajima, S. T., Pappadakis, J., Archer, D. F. 2016; 93 (1): 52?57

    Abstract

    Safe and effective contraceptive options for obese women are becoming more important due to the obesity epidemic within the United States. This study evaluated the impact of body mass index (BMI) on efficacy, safety and bleeding patterns during use of an ultra-low-dose combined oral contraceptive (COC).Data are from a Phase 3 clinical efficacy and safety study of an ultra-low-dose COC containing 1.0-mg norethindrone acetate and 10-mcg ethinyl estradiol. Pearl Indices, adverse events and bleeding profile were calculated for BMI ranges of <25, 25-30 and >30 kg/m(2).Of the 1581 participants included in the analysis, 28.3% were overweight, and 18.0% were obese. For women aged 18-45 years, the Pearl Indices were 2.49, 2.32 and 1.89 for women with a BMI <25, 25-30 and >30 kg/m(2), respectively. The ultra-low dose of ethinyl estradiol did not impact scheduled bleeding or intensity of bleeding, but we observed a slight decline in amenorrhea and slight increase in unscheduled bleeding in obese women compared with other BMI categories.Our analysis of an ultra-low-dose COC did not find clinically important differences in contraceptive failure rates, adverse events or bleeding profile with increasing BMI.Our analysis of an ultra-low ethinyl estradiol dose COC did not find clinically important differences in contraceptive failure rates, adverse events or bleeding profile with increasing BMI. An ultra-low-dose COC provides another safe and effective contraceptive option for obese women.

    View details for PubMedID 26410176

  • Hormonal and Nonhormonal Treatment of Vasomotor Symptoms OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA Krause, M. S., Nakajima, S. T. 2015; 42 (1): 163-?

    Abstract

    This article focuses on the cause, pathophysiology, differential diagnosis of, and treatment options for vasomotor symptoms. In addition, it summarizes important points for health care providers caring for perimenopausal and postmenopausal women with regard to health maintenance, osteoporosis, cardiovascular disease, and vaginal atrophy. Treatment options for hot flashes with variable effectiveness include systemic hormone therapy (estrogen/progestogen), nonhormonal pharmacologic therapies (selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, clonidine, gabapentin), and nonpharmacologic therapy options (behavioral changes, acupuncture). Risks and benefits as well as contraindications for hormone therapy are further discussed.

    View details for DOI 10.1016/j.ogc.2014.09.008

    View details for Web of Science ID 000350936900014

    View details for PubMedID 25681847

Footer Links:

Stanford Medicine Resources: